Terms: = Kidney tumors AND BCL2, Bcl-2, 596, ENSG00000171791 AND Treatment
253 results:
1. Molecular and functional characterization of reversible-sunitinib-tolerance state in human renal cell carcinoma.
Zaccagnino A; Vynnytska-Myronovska B; Stöckle M; Junker K
J Cell Mol Med; 2024 May; 28(9):e18329. PubMed ID: 38693863
[TBL] [Abstract] [Full Text] [Related]
2. Identification of Erzhu Jiedu Recipe and its molecular mechanism underlying inhibited human hepatoma cells by UHPLC-Q-Exactive Orbitrap HRMS and network pharmacology.
Wang F; Mai J; Wang H; Xu Y; Zhou X; Xie Z; Yu B; Liu P; Liu W; Cheng Y
J Ethnopharmacol; 2024 May; 325():117893. PubMed ID: 38336184
[TBL] [Abstract] [Full Text] [Related]
3. Pterostilbene and 6-shogaol exhibit inhibitory effects on sunitinib resistance and motility by suppressing the RLIP76-initiated Ras/ERK and Akt/mTOR pathways in renal cancer cells.
Chiang IC; Chen SY; Hsu YH; Shahidi F; Yen GC
Eur J Pharmacol; 2024 Mar; 967():176393. PubMed ID: 38325792
[TBL] [Abstract] [Full Text] [Related]
4. Targeting apoptosis and unfolded protein response: the impact of β-hydroxybutyrate in clear cell renal cell carcinoma under glucose-deprived conditions.
Roohy F; Siri M; Kohansal K; Ghalandari A; Rezaei R; Maleki MH; Shams M; Monsef A; Dastghaib S
Mol Biol Rep; 2024 Jan; 51(1):168. PubMed ID: 38252187
[TBL] [Abstract] [Full Text] [Related]
5. Baicalein improves the chemoresistance of ovarian cancer through regulation of CirSLC7A6.
Li S; Yi Z; Li M; Zhu Z
J Ovarian Res; 2023 Nov; 16(1):212. PubMed ID: 37940982
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
7. Modulation of mammary tumour progression using murine model by ethanol root extract of Saussurea costus (falc.) lipsch.
Kumar R; Bhardwaj P; Soni M; Singh R; Choudhary S; Virmani N; Asrani RK; Patial V; Sharma D; Gupta VK; Tripathi BN
J Ethnopharmacol; 2024 Jan; 319(Pt 3):117302. PubMed ID: 37858751
[TBL] [Abstract] [Full Text] [Related]
8. [Mechanism of nuclear protein 1 in the resistance to axitinib in clear cell renal cell carcinoma].
Liu YC; Wu ZL; Ge LY; DU T; Wu YQ; Song YM; Liu C; Ma LL
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 55(5):781-792. PubMed ID: 37807730
[TBL] [Abstract] [Full Text] [Related]
9. BNIP3 as a potential biomarker for the identification of prognosis and diagnosis in solid tumours.
Yu Q; Fu W; Fu Y; Ye W; Yan H; Yu Z; Li R; Cai Y; Chen Y; Wang L; Wei X; Chen Y; Zhang Y; Ying H; Tang F; Dai F; Han W
Mol Cancer; 2023 Aug; 22(1):143. PubMed ID: 37649051
[TBL] [Abstract] [Full Text] [Related]
10. Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases.
Schoenfeld DA; Moutafi M; Martinez S; Djureinovic D; Merkin RD; Adeniran A; Braun DA; Signoretti S; Choueiri TK; Parisi F; Hurwitz M; Rimm DL; Wei W; Jilaveanu L; Kluger HM
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586773
[TBL] [Abstract] [Full Text] [Related]
11.
Samankul A; Senawong G; Utaiwat S; Prompipak J; Woranam K; Phaosiri C; Sripa B; Senawong T
Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512080
[No Abstract] [Full Text] [Related]
12. PI3K/Akt signaling in urological cancers: Tumorigenesis function, therapeutic potential, and therapy response regulation.
Rezaei S; Nikpanjeh N; Rezaee A; Gholami S; Hashemipour R; Biavarz N; Yousefi F; Tashakori A; Salmani F; Rajabi R; Khorrami R; Nabavi N; Ren J; Salimimoghadam S; Rashidi M; Zandieh MA; Hushmandi K; Wang Y
Eur J Pharmacol; 2023 Sep; 955():175909. PubMed ID: 37490949
[TBL] [Abstract] [Full Text] [Related]
13. [Cordycepin, a metabolite of
Zheng Q; Shao Y; Zheng W; Zou Y
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Jun; 43(6):873-878. PubMed ID: 37439158
[TBL] [Abstract] [Full Text] [Related]
14.
Choi EY; Jung GH; Woo JS; Lee JH; Han SH; Jung SH; Kim SM; Kim EH; Ro JY; Kim KJ; Jung JY
Anticancer Res; 2023 Jul; 43(7):3047-3056. PubMed ID: 37351981
[TBL] [Abstract] [Full Text] [Related]
15. Computational docking and
Otifi HM; Alshyarba M; Fayi MA; Dera AA; Rajagopalan P
Oncol Res; 2021; 29(3):217-227. PubMed ID: 37304673
[TBL] [Abstract] [Full Text] [Related]
16. Knocking down NSUN5 inhibits the development of clear cell renal cell carcinoma by inhibiting the p53 pathway.
Li L; Li M; Zheng J; Li Z; Chen X
Aging (Albany NY); 2023 Jun; 15(11):4757-4773. PubMed ID: 37263638
[TBL] [Abstract] [Full Text] [Related]
17. 3-Bromopyruvate Inhibits the Growth and Glucose Metabolism of TNBC Xenografts in Nude Mice by Targeting c-Myc.
Pan JM; Li JC; Yang C; Xiao WF; Li QS; Luo XH; Zhang XD
Anticancer Agents Med Chem; 2023; 23(12):1421-1428. PubMed ID: 37038711
[TBL] [Abstract] [Full Text] [Related]
18. Ex Vivo Drug Testing in Patient-derived Papillary Renal Cancer Cells Reveals EGFR and the bcl2 Family as Therapeutic Targets.
Angori S; Banaei-Esfahani A; Mühlbauer K; Bolck HA; Kahraman A; Karakulak T; Poyet C; Feodoroff M; Potdar S; Kallioniemi O; Pietiäinen V; Schraml P; Moch H
Eur Urol Focus; 2023 Sep; 9(5):751-759. PubMed ID: 36933996
[TBL] [Abstract] [Full Text] [Related]
19. Association of Direct-Acting Antiviral Therapy With Liver and Nonliver Complications and Long-term Mortality in Patients With Chronic Hepatitis C.
Ogawa E; Chien N; Kam L; Yeo YH; Ji F; Huang DQ; Cheung R; Nguyen MH
JAMA Intern Med; 2023 Feb; 183(2):97-105. PubMed ID: 36508196
[TBL] [Abstract] [Full Text] [Related]
20. The effect of mesenchymal stem cells-derived exosomes on the prostate, bladder, and renal cancer cell lines.
Rezaeian A; Khatami F; Heidari Keshel S; Akbari MR; Mirzaei A; Gholami K; Mohammadi Farsani R; Aghamir SMK
Sci Rep; 2022 Dec; 12(1):20924. PubMed ID: 36463254
[TBL] [Abstract] [Full Text] [Related]
[Next]
